Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

References

• Website of the Belgian National Institute of statistics (http://www.statbel.fgov.be/) 2002.
   Google Scholar
• De Henauw S, De Bacquer D, de Smet P et al. Trends in coronary heart disease in two Belgian areas: results from the MONICA Ghent-Charleroi study. Journal of Epidemiology and Community Health 1999; 53: 89–99.
   PubMed Web of Science ®Google Scholar
• Website of the Belgian Scientific Institute of Public Health (http://www.iph.fgov.be/epidemio/mor bidat/NL/) 2002
   Google Scholar
• Verhaeghe R. Epidémiologie et pronstic de l’artériopathie oblitérante des membres inférieurs. Drugs 1998; 56 (Suppl. 3): 1–10.
   PubMedGoogle Scholar
• Dormandy J. Natural history of intermittent claudication. Hospital Update 1991; 17: 314–320.
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.
   PubMed Web of Science ®Google Scholar
• Hlatky MA. Role of economic models in randomised clinical trials. American Heart Journal 1999; 137 (Suppl.): S41–S46.
   Web of Science ®Google Scholar
• Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation. Bridging the gap between clinical research and policy making. Pharmacoeconomics 1999; 16: 449–458.
   PubMed Web of Science ®Google Scholar
• Belgian Society for Pharmacoepidemiology. Standard report format for economic evaluation of pharmaceuticals. Belgium
   Google Scholar
• Saskatchewan Health. Saskatchewan’s health information resources. Research Services. Strategic programs branch, Canada 1995.
   Google Scholar
• Institut Nationale d’Assurance Maladie- Invalidité. Noménclature 2002.
   Google Scholar
• Répertoire Commenté des médicaments de Belgique: http://www.bcfi.be/
   Google Scholar
• Doubilet P, Begg CB, Weinstein MC, Braun P et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Medical Decision Making 1985; 5: 155–177.
   Google Scholar
• Frend JE, Walpole RE. Mathematical Statistics. Prentice-Hall International, 1987.
   Google Scholar
• Clark DE. Computational methods for probabilistic decision trees. Computers and Biomedical Research 1997; 30: 19–33.
   PubMedGoogle Scholar
• Law AM, Kelton WD. Simulation Modelling and Analysis. New York, NY: McGraw-Hill, 1991.
   Google Scholar
• Postma MJ, Heijnen ML, Beutels P et al. Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis. Ned Tijdschr Geneeskd 2002; 146: 855–889.
   PubMedGoogle Scholar
• Young M, Plosker GL. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 2001; 19: 1227–1259.
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Will BP, Evans WK et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. Journal of the National Cancer Institute 2000; 92: 1321–1329.
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Born GVR, D’Agostino RB et al. Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 1999; 30: 1716–1721.
   PubMed Web of Science ®Google Scholar
• Marissal JP, Selke B, Lebrun T. Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 2000; 18: 185–200.
   PubMed Web of Science ®Google Scholar
• Oster G, Huse DM, Lacy MJ et al. Cost- effectiveness of ticlodipine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149–1156.
   PubMed Web of Science ®Google Scholar
• Chambers M, Hutton J, Gladman J. Cost- effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics 1999; 16: 577–593.
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischaemic attack. Archives of Internal Medicine 2000; 160: 2773–2778.
   Google Scholar
• Hadelmann R, Szucs T.D, Luscher T. Rentabilité du clopidogrel dans la prévention secondaire cardio-vasculaire: une analyse coût-efficacité sur la base de l’étude CAPRIE. Medical Hygiene 2001; 59: 1749–1754.
   Google Scholar
• Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine 2002; 346: 1800–1806.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. New England Journal of Medicine 2003; 348: 561.
   Google Scholar
• Muls E, Van Ganse E, Closon MC. Cost- effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 (Suppl.): S111 –S116.
   PubMed Web of Science ®Google Scholar
• Franzosi MG, Brunetti M, Marchioli R et al. GISSI-Prevenzione Investigators. Cost- effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)- Prevenzione Trial. Pharmacoeconomics 2001; 19: 411–420
   PubMed Web of Science ®Google Scholar
• Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2003; 24: 28.
   PubMed Web of Science ®Google Scholar
• Brown RE, Henderson RA, Koster D et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using IntegrilinTherapy. European Heart Journal 2002; 23: 50–58.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. American Journal of Medicine 1999; 107: 568–572.
   PubMed Web of Science ®Google Scholar
• Salomaa V, Rosamond W, Mahonen M. Decreasing mortality from acute myocardial infarction: effect of incidence and prognosis. Journal of Cardiovascular Risk 1999; 6: 69–75.
   PubMedGoogle Scholar